In order to directly compare hard renal outcomes between pioglitazone users and SGLT2-i users, our enrollment criteria were similar to those used in the CREDENCE trials (T2DM patients with eGFR 30–90 ml/min/m2 and UACR 300–5000 mg/g). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.